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STUDY QUESTION: What is the role of the hypothalamic neuropeptide neurokinin B (NKB) and its interaction with kisspeptin on
GnRH/LH secretion in women with polycystic ovary syndrome (PCOS)?
SUMMARY ANSWER: Administration of neurokinin 3 receptor antagonist (NK3Ra) for 7 days reduced LH and FSH secretion and LH
pulse frequency in women with PCOS, whilst the stimulatory LH response to kisspeptin-10 was maintained.
WHAT IS KNOWN ALREADY: PCOS is characterized by abnormal GnRH/LH secretion. NKB and kisspeptin are master regulators of
GnRH/LH secretion, but their role in PCOS is unclear.
STUDY DESIGN, SIZE, DURATION: The NK3Ra MLE4901, 40mg orally twice a day, was administered to women with PCOS for 7
days (n¼ 8) (vs no treatment, n¼ 7). On the last day of NK3Ra administration or the equivalent day in those not treated, women were
randomized to 7-h kisspeptin-10 (4 mg/kg/h i.v.) or vehicle infusion. This was repeated with the alternate infusion in a subsequent cycle.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Subjects were women with PCOS, studied in a Clinical Research Facility.
Reproductive hormones were measured before and after NK3Ra administration. On the last day of NK3Ra administration (or the equiva-
lent cycle day in untreated women), all women attended for an 8-h frequent blood sampling to allow analysis of the pulsatile LH secretion.
MAIN RESULTS AND THE ROLE OF CHANCE: NK3Ra reduced LH secretion (4.0§ 0.4 vs 6.5§ 0.8 IU/l, P< 0.05) and pulse fre-
quency (0.5§ 0.1 vs 0.8§ 0.1 pulses/h, P< 0.05); FSH secretion was also reduced (2.0§ 0.3 vs 2.5§ 0.4 IU/l, P< 0.05). Without
NK3Ra pre-treatment, kisspeptin-10 increased LH secretion (5.2§ 0.5 to 7.8§ 1.0 IU/L, P< 0.05), with a positive relationship to oestra-
diol concentrations (r2 ¼ 0.59, P< 0.05). After NK3Ra administration, the LH response to kisspeptin-10 was preserved (vehicle 3.5§ 0.3
vs 9.0§ 2.2 IU/l with kisspeptin-10, P< 0.05), but the positive correlation with oestradiol concentrations was abolished (r2 ¼ 0.07, ns. af-
ter NK3Ra). FSH secretion was increased by kisspeptin-10 after NK3Ra treatment, but not without NK3Ra treatment.
LIMITATIONS, REASONS FOR CAUTION: The study did not explore the dose relationship of the effect of NK3R antagonism. The
impact of obesity or other aspects of the variability of the PCOS phenotype was not studied due to the small number of subjects.
WIDER IMPLICATIONS OF THE FINDINGS: These data demonstrate the interactive regulation of GnRH/LH secretion by NKB and
kisspeptin in PCOS, and that the NKB system mediates aspects of oestrogenic feedback.
STUDY FUNDING/COMPETING INTEREST(S):Wellcome Trust through Scottish Translational Medicine and Therapeutics Initiative
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Human Reproduction, Vol.35, No.6, pp. 1421–1431, 2020
Advance Access Publication on June 8, 2020 doi:10.1093/humrep/deaa104
ORIGINAL ARTICLE Reproductive endocrinology
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/35/6/1421/5854484 by guest on 09 July 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
TRIAL REGISTRATION NUMBER: N/A.
Key word: neurokinin B / kisspeptin / LH pulsatility / PCOS / GnRH
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrinop-
athy in women of reproductive age and the leading cause of anovula-
tory infertility (Sirmans and Pate, 2013). The clinical syndrome is
characterized by the presence of some or all of (i) chronic anovulation
with oligo/amenorrhoea; (ii) clinical and/or biochemical hyperandroge-
naemia; and/or (iii) polycystic appearance of the ovaries (Rotterdam,
2004; Teede et al., 2018). It is a heterogenous condition with multifac-
torial pathophysiology, including genetic, environmental, neuroendo-
crine and metabolic components, although those underpinnings and
their relative importance remain unclear (Goodarzi et al., 2011; Hayes
et al., 2015). Treatment is essentially symptomatic, and further insight
into the mechanisms underlying the central endocrinopathy has poten-
tial for the development of new therapies.
Women with PCOS often show a neuroendocrine disturbance, with
increased LH pulse secretion, with little effect on FSH secretion, pre-
sumably reflecting a similar perturbation in GnRH neuronal activity
(Santen and Bardin, 1973; Rebar et al., 1976; Marshall et al., 2001;
Moore and Campbell, 2017). This LH hyper-pulsatility contributes to
increased thecal androgen secretion and failure of ovulation, constitut-
ing a pivotal pathogenic role in the syndrome (Marshall et al., 2001;
Caldwell et al., 2017). Kisspeptin–neurokinin B (NKB) pathways have
emerged as master regulators of GnRH and LH secretion (Pinilla et al.,
2012; Skorupskaite et al., 2014; Clarkson et al., 2017). Patients with
loss-of-function mutations in kisspeptin, NKB and their respective
receptors (KISS1R and NK3R) show pubertal delay (de Roux et al.,
2003; Seminara et al., 2003; Topaloglu et al., 2009; Topaloglu et al.,
2012), whereas precocious puberty is seen in those with activating
mutations in KISS1R (Teles et al., 2008). In a randomized controlled
trial, neurokinin 3 receptor antagonist (NK3Ra) administration in
women with PCOS decreased the frequency of LH pulses (indicative
of pulsatile GnRH release) and also LH and testosterone concentra-
tions (George et al., 2016). This is in concordance with a suppressive
action of NKB antagonism on pulsatile LH secretion shown in post-
menopausal women with hot flushes (Skorupskaite et al., 2018b), in a
model of the mid-cycle LH surge in healthy women (Skorupskaite
et al., 2016) and in gonadectomized animals (Fraser et al., 2015; Li
et al., 2015). These findings clearly illustrate NKB modulation of LH se-
cretion via GnRH, and it is possible that dysregulation of NKB signalling
may play a role in the neuroendocrine pathogenesis of PCOS.
NKB signalling is closely interlinked with hypothalamic kisspeptin
pathways, with overlapping expression in hypothalamic neurones im-
pinging on GnRH neurones (Clarkson and Herbison, 2006; Goodman
et al., 2007; Hrabovszky et al., 2010). Where these neurones also ex-
press the opioid dynorphin, they are termed KNDy neurones. The
functional interactions of these pathways are incompletely determined.
In patients with inactivating mutations in NKB (TAC) and its receptor
(TAC3), with slow GnRH secretion, exogenous kisspeptin-10 restored
LH pulse frequency (Young et al., 2013). Kisspeptin-10 stimulated LH
secretion after it was decreased during NK3Ra administration in
healthy men (Skorupskaite et al., 2017). This and concordant data
from animal models have led to the conclusion that NKB signalling is
functionally upstream of kisspeptin in regulating GnRH secretion
(Billings et al., 2010; Corander et al., 2010; Garcia-Galiano et al., 2012;
Navarro et al., 2011). However, in postmenopausal women with high
LH output, the gonadotropin response to kisspeptin-10 before and af-
ter pharmacological blockage of NK3R was limited (Skorupskaite et al.,
2018b). Whilst these data support an overall hierarchy whereby NKB
is functionally afferent to kisspeptin, the interactions between those hy-
pothalamic neuropeptides in modulating GnRH/LH secretion are
unclear. There are no data on this interaction in women with PCOS, a
human disease model of LH hyper-secretion.
Kisspeptin neurones are critical in mediating the effects of sex-
steroid feedback on GnRH secretion (Dhillo et al., 2007; Jayasena
et al., 2011; Chan et al., 2012; George et al., 2012). The LH response
to kisspeptin is greatest in the late follicular phase of the menstrual cy-
cle (Dhillo et al., 2007; Jayasena et al., 2011; Chan et al., 2012) and is
positively related to circulating oestradiol levels (Narayanaswamy et al.,
2016a; Skorupskaite et al., 2016). However, this relationship between
kisspeptin-induced LH response and oestradiol concentrations is dis-
rupted with NKB antagonism in healthy women, indicating a key role
of NKB in modulating the effect of the sex-steroid environment
(Skorupskaite et al., 2016). Despite clear roles for NKB and kisspeptin
in regulating LH secretion, the relative contribution of the NKB-
kisspeptin pathway to the pathophysiology of PCOS remains uncertain,
and may have therapeutic potential. We therefore hypothesized that
NK3R antagonism would affect LH secretion in women with PCOS
through modification of aspects of its pulsatile secretion, and that a
functionally upstream site of action would not prevent the stimulatory
effect of kisspeptin on LH secretion, but that the LH response to kiss-
peptin would be modified, indicating a role of NK3R signalling in the
regulation of that response to circulating oestradiol levels.
Materials and Methods
Participants
Ten otherwise healthy women with PCOS, aged 19–31 years, with a
body mass index of 20–40 kg/m2 and a last menstrual period 2–7
months ago, were recruited into the study (Table I); all provided in-
formed written consent. Five of the women participated in both arms
(NK3Ra treatment and no treatment group) of the study, thus there
were a total of 15 cycles in the study (8 with NK3Ra and 7 without
treatment). Subjects needed to meet at least two of the following
Rotterdam criteria after exclusion of related disorders of menstrual ir-
regularity: (i) oligomenorrhoea/amenorrhoea for at least 1 year; (ii)
clinical and/or biochemical signs of hyperandrogenism (above labora-
tory normal of total testosterone i.e. >1.9 nmol/l, measured by LC-
MS) or Free Androgen Index >6.5); and/or (iii) polycystic ovaries
(12 follicles per ovary and/or ovarian volume 10ml) documented
on high resolution transvaginal ultrasound scan (Rotterdam, 2004). All
subjects in the study were oligo/amenorrhoeic (see Table I for
1422 Skorupskaite et al.
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phenotypes). Participants were not taking any hormonal contraception
nor had an intrauterine device in situ. They otherwise had a normal
physical examination, and their full blood count, renal function and
electrolytes, liver function and electrocardiogram were within normal
limits.
Study drugs
Medroxyprogesterone acetate (Pfizer, Surrey, UK) was used to induce
withdrawal menstruation. Kisspeptin-10 was custom synthesized under
GMP standards (Bachem GmBH, Weil am Rhein, Germany) (George
et al., 2011), and 1 mg kisspeptin-10 was dissolved in 5 ml sterile nor-
mal (0.9%) saline immediately before infusion. The syringe and line for
infusion were first coated for 30 min with kisspeptin-10 to minimize
peptide loss from adherence to the plastic. Sterile normal saline was
infused as vehicle. The NK3Ra MLE4901 (previously termed
AZD4901, Astra-Zeneca, Macclesfield, UK) was administered orally at
40 mg twice daily. This dose of MLE4901 reduced LH secretion in
normal women and in women with PCOS (George et al., 2016;
Skorupskaite et al., 2016).
Protocol
Medroxyprogesterone acetate, 10 mg twice daily orally for 7 days,
was administered to induce a withdrawal bleed. In eight treatment
cycles, women received NK3Ra (MLE4901) 40 mg oral twice daily
starting from Cycle day 1–2 for 7 days, and in seven cycles, they re-
ceived no treatment (Fig. 1). Volunteers attended the clinical research
facility on Day 6 or 7 of NK3Ra dosing (Cycle day 6–8) in the treat-
ment group and on the equivalent day in the no treatment group.
After an hour of baseline sampling, volunteers were randomized (using
sealed envelopes) to receive a continuous intravenous infusion of
kisspeptin-10 (4mg/kg/h) or vehicle for 7 h. In the NK3Ra treatment
group, the last dose of MLE4901 was taken on the morning of
kisspeptin-10 or vehicle administration. All women returned to receive
the alternate infusion of kisspeptin-10 or vehicle after at least a month
wash out period and repeated induction of menstruation with
medroxyprogesterone followed by administration of NK3Ra or no
treatment, as they have received in the previous cycle.
Blood sampling and hormone assays
Peripheral venous blood was sampled between 8 and 9 am for LH,
FSH and oestradiol in the treatment group on the day of commencing
............................................................................................................................................................................................................................
Table I Baseline characteristics of thewomenwith PCOSenrolled in the study.
Subject Age
(years)
BMI
(kg/m2)
Months
since LMP
LH
(IU/l)
FSH
(IU/l)
Oestradiol
(pmol/l)
Testosterone
(nmol/l)
FAI PCOS
phenotype
1 31 38 7 17.9 6.6 241 1.9 7.9 B
2 30 30 2 11.6 5.8 95 0.9 7.5 A
3 30 44 14 16.4 6.9 218 1.8 18 A
4 24 40 8 6.7 4.9 180 1.9 9.5 A
5 19 35 3 15.9 6.9 250 2.4 7.3 B
6 30 20 2 12 3 273 1.8 1.9 A
7 21 38 2 9.7 3.8 265 1.1 4.2 D
8 26 33 5 7.8 3.9 152 2.4 6.9 B
9 28 36 3 6.1 3.2 126 1.3 8.7 A
10 27 34 12 5.7 3.9 167 1 6.3 B
Mean § SEM 27 § 1.3 35 § 2.1 6 § 1.4 11.0 § 0.4 4.9 § 0.5 197 § 19.5 1.7 § 0.2 7.8 § 1.3
All women were oligo/amenorrhoeic. Phenotype A ¼ oligo/amenorrhoea, clinical or biochemical hyperandrogenism and polycystic ovaries; Phenotype B ¼ oligo/amenorrhoea and
hyperandrogenism; Phenotype D ¼ oligo/amenorrhoea and polycystic ovaries. Reference range for testosterone, 0.3–1.9 nmol/l, and for FAI (free androgen index), <6.5.
FAI, free androgen index; LMP, last menstrual period; NK3Ra, neurokinin 3 receptor antagonist; PCOS, polycystic ovary syndrome.
Figure 1 Study protocol diagram. Following medroxyproges-
terone withdrawal menstruation, in eight treatment cycles, women
received neurokinin 3 receptor antagonist (NK3Ra; MLE4901) 40 mg
oral twice daily starting from Cycle day 1–2 for 7 days, and in 7
cycles, women received no treatment. On Day 6 or 7 of NK3Ra
dosing in the treatment group and the equivalent day in the no treat-
ment group, women were randomized to 7 h kisspeptin-10 or vehi-
cle infusion, returning for alternate infusion after subsequent
medroxyprogesterone induced menstruation. Reproductive hor-
mones were measured throughout the study and LH pulsatility was
assessed during 10-min frequent blood sampling for 8 h on the infu-
sion day.
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NK3Ra. Seven days later on the last day of NK3Ra administration (or
equivalent cycle day in the untreated women), all women attended for
an 8-h visit (starting 8–9 am), blood samples were collected via an in-
dwelling i.v. cannula at 10 min intervals for assessments of LH pulsatile
secretion; FSH and oestradiol were measured hourly.
Blood samples were centrifuged at 4C for 10 min at 3000 rpm and
serum was frozen at 20C or below until analysis. LH and FSH were
measured by ELISA as previously described (George et al., 2011) 17b-
oestradiol was measured on a Roche Cobas E411 immunoassay auto-
mated analyser (Roche Diagnostics, Burgess Hill, UK).
The number of LH pulses, secretory mass of LH per pulse, and the
basal (non-pulsatile) and pulsatile (integral of dual amplitude and fre-
quency regulation) LH secretion were identified by an established
deconvolutional algorithm with cluster analysis (93% sensitivity and
specificity) blinded to treatment allocation, and ApEn was quantified as
a measure of secretory regularity (Veldhuis et al., 2008; Liu et al.,
2009).
Statistical analysis
The study size was determined from similar investigations of LH pulsa-
tile secretion (George et al., 2011, 2012). Mean LH, FSH and oestra-
diol concentrations pre- and post-NK3Ra treatment were compared
using the Student’s paired t-test.
Mean hourly hormone concentrations during 8 h of kisspeptin-10 or
vehicle infusion were compared using two-way ANOVA with repeated
measures followed by Bonferroni’s post hoc multiple comparisons test.
Pearson’s correlation coefficient was computed to assess the relation-
ship between oestradiol concentrations and LH response to
kisspeptin-10 with and without the NK3Ra.
Characteristics of LH pulsatile secretion were compared using
Student’s t-test or Wilcoxon-matched pairs-signed rank test for paired
data and unpaired t-test or Mann–Whitney test for unpaired data,
depending on the normality of distribution of the data.
Data are presented as mean § SEM. Differences were regarded as
significant at a two-sided P< 0.05. The statistical software package
GraphPad Prism (GraphPad, San Diego, CA, USA) was used.
Ethical approval
The study protocol was approved by South East Scotland Research
Ethics Committee (Ref: 09/S1101/67) and all women gave consent, in
writing.
Results
NK3Ra decreases gonadotropin secretion
NK3Ra decreased LH concentrations from 6.5§ 0.8 IU/l pre-
treatment to 4.0§ 0.4 IU/l after 7 days of NK3Ra administration
(P< 0.05) (Fig. 2A). Analysis of LH at hourly intervals for 8 h after the
last NK3Ra dose also showed that overall LH secretion was lower in
NK3Ra-treated women compared to no treatment (P< 0.0001,
Fig. 2D), although post hoc analysis indicated no significant differences
in LH levels at any individual hourly time point.
Serum FSH levels were reduced with NK3Ra administration when
compared to pre-treatment concentrations (pre-NK3Ra 2.5§ 0.4 vs
post-NK3Ra 2.0§ 0.3 IU/l, P< 0.05) (Fig. 2B). Analysis of FSH at
hourly intervals for 8 h after the last dose showed that overall FSH se-
cretion was also lower with NK3Ra treatment compared to no treat-
ment (P< 0.0001, Fig. 2E). Oestradiol concentrations were unaffected
by the NK3Ra (Fig. 2C and F).
Effects of kisspeptin-10 on gonadotropin
secretion
Kisspeptin-10 stimulated LH secretion, which was sustained through-
out 7 h of kisspeptin-10 administration (P< 0.05) (Fig. 2D). Kisspeptin-
10 increased LH secretion from 5.2§ 0.5 IU/l pre-infusion to
7.8§ 1.0 IU/l at the end of infusion (P< 0.05) (Fig. 2G), compared to
5.0§ 0.8 IU/l after infusion with vehicle (P< 0.001). FSH secretion
was unaffected by kisspeptin-10 (Fig. 2E and H).
Serum oestradiol levels were higher after kisspeptin-10 administra-
tion compared to pre-treatment concentrations (pre-infusion 75§ 20
vs post-infusion 135§ 21 pmol/l, P< 0.001) (Fig. 2I), although they
were not different compared to concentrations after infusion with ve-
hicle (7 h of kisspeptin-10: 135§ 21 vs vehicle 114§ 27 pmol/l, ns.)
(Fig. 2F).
Effect of NK3Ra on kisspeptin-10 induced
gonadotropin secretion
Following treatment with NK3Ra, kisspeptin-10 also stimulated LH re-
lease (end of kisspeptin-10: 9.0§ 2.2 vs vehicle 3.5§ 0.3 IU/l,
P< 0.05, Fig. 2D). This increase was similar to LH concentrations stim-
ulated with kisspeptin-10 infusion alone (end of kisspeptin-10 with
NK3Ra: 9.0§ 2.2 vs kisspeptin-10 alone 7.8§ 1.0 IU/l, ns., Fig. 2D).
In the presence of the NK3Ra, kisspeptin-10 stimulated FSH secre-
tion (end of kisspeptin-10 infusion 2.8§ 0.4 IU/l vs 2.2§ 0.4 pre-
infusion and 2.0§ 0.3 with vehicle, both P< 0.05, Fig. 2E).
NK3Ra abolishes oestradiol dependency of
kisspeptin-10 response
The effect of NK3Ra in the relationship between the LH response to
kisspeptin-10 and oestradiol exposure was investigated by analysing
LH concentration at the end of kisspeptin-10 infusion in relation to
oestradiol concentration at the start of the kisspeptin-10 infusion.
There was a strong positive correlation between LH response to
kisspeptin-10 and oestradiol concentration in women not treated with
the NK3Ra (r2 ¼ 0.59, P< 0.05) (Fig. 3). However, in NK3Ra-treated
women, the LH response to kisspeptin-10 showed no such relation-
ship (r2 ¼ 0.07, ns.).
Interaction between kisspeptin-10 and
NK3Ra in regulation of LH pulsatile
secretion
Exemplars of LH pulse profiles during vehicle and kisspeptin-10 infu-
sion with and without NK3Ra treatment are shown in Fig. 4A. LH
pulse frequency was decreased to 0.5§ 0.1 pulses/h after NK3Ra
treatment compared to 0.8§ 0.1 pulses/h in the no treatment group
(P< 0.05) (Fig. 4A and B). Kisspeptin-10 alone had no effect on LH
pulse frequency, but in women treated with NK3Ra, administration of
1424 Skorupskaite et al.
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Figure 2 Reproductive hormone response to administration of NK3Ra or no treatment followed by kisspeptin/vehicle infusion
cycles in women with polycystic ovary syndrome. (A–C) Mean LH (A), FSH (B) and oestradiol (C) concentrations at the end of NK3Ra treat-
ment comparted to pre-treatment day (n ¼ 8). (D–F) Time course analysis of frequent blood sampling of LH (D), FSH (E) and oestradiol (F) levels
before (Time 0) and during 7 h of vehicle or kisspeptin-10 infusion in the treatment (NK3Ra) group (n ¼ 8) and no treatment group (n ¼ 7).
Kisspeptin-10 stimulated LH secretion in both vehicle and NK3Ra-treated women (P < 0.05) but did not affect FSH secretion. Serum oestradiol levels
were higher after kisspeptin-10 administration compared to pre-treatment concentrations (P < 0.001), although were not different compared to that
after infusion with vehicle. LH levels were lower in NK3Ra compared with vehicle-treated women (P < 0.0001), although Bonferroni’s post hoc multi-
ple comparison test found no significant changes at specific time points. (G and H) Mean LH (G), FSH (H) and oestradiol (I) concentrations at the
end of kisspeptin-10 treatment comparted to pre-treatment (n ¼ 7). Data are presented as mean § SEM. *P < 0.05; ***P < 0.001. Mean differences
at specific time points for vehicle versus kisspeptin-10 infused in no NK3Ra-treated women: *P < 0.05, ***P < 0.001. For vehicle vs kisspeptin-10 in
NK3Ra-treated women: WP < 0.05.
NKB-kisspeptin axis in PCOS 1425
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/35/6/1421/5854484 by guest on 09 July 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..kisspeptin-10 increased LH pulse frequency to 0.8§ 0.1 pulses/h
(P< 0.05 vs NK3Ra with vehicle infusion) (Fig. 4B).
NK3Ra antagonist alone did not reduce secretory mass of LH per
pulse (Fig. 4C). Secretory mass per pulse was increased during infusion
of kisspeptin-10 compared with vehicle (P< 0.05) but not following
pre-treatment with the NK3Ra (Fig. 4C).
Basal LH secretion was also decreased with NK3Ra treatment
(P< 0.05 vs vehicle in the no treatment group, Fig. 4D) but there was
no effect on pulsatile LH secretion (Fig. 4E). Kisspeptin-10 increased
pulsatile but not basal LH secretion (P< 0.05 vs vehicle, Fig. 4D and
E). Kisspeptin-10 infusion in NK3Ra-treated women induced no
change in basal or pulsatile LH secretion.
The regularity of LH secretory pattern was assessed by approximate
entopy (ApEn). Both NK3Ra and kisspeptin-10 infusion imposed
greater orderliness (lower ApEn) in LH secretion (P< 0.05, Fig. 4F)
with no additional change with the combination of treatments.
Tolerability and safety
The NK3Ra, MLE4901, was well tolerated with no treatment discon-
tinuations. Haematology and biochemistry safety parameters remained
stable in all subjects throughout the study period.
Discussion
We, here, investigated the interaction between kisspeptin and NKB in
the modulation of pulsatile GnRH/LH secretion in women with
PCOS, to explore the neuroendocrine component of the pathophysi-
ology of this syndrome. Pharmacological blockage of NKB-NK3R sig-
nalling decreased both LH and FSH secretion and slowed LH
pulsatility. Although kisspeptin-10 stimulated LH release to a similar
degree with and without the NK3Ra treatment, the strong relationship
between oestradiol and LH response to kisspeptin was abolished in
the presence of the NK3Ra.
These data confirm that NK3Ra treatment in women with PCOS
reduced LH secretion, indicative of suppressed hypothalamic GnRH
pulsatile secretion. This observation is consistent throughout animal
studies (Fraser et al., 2015; Li et al., 2015) and in healthy women in
states of fast and slow LH pulse frequency and in varying sex-steroid
environments (George et al., 2016; Skorupskaite et al., 2016, 2018a,b).
In a randomized double blinded, placebo-controlled clinical trial in
women with PCOS administering the same NK3Ra at the same dose
and for the same 7 day duration, LH pulse frequency was reduced, as
were LH secretion and testosterone secretion, whilst FSH levels
remained unchanged (George et al., 2016). Here, we show suppressed
FSH secretion on Day 7 of NK3Ra treatment assessed over 8 h of fre-
quent blood sampling post dose, which may have been missed when
single time-point FSH concentrations were compared at baseline and
post treatment in previous studies. This is consistent with FSH secre-
tion being modulated by non-pulsatile GnRH release as basal LH se-
cretion was also suppressed by the NK3Ra. In women with PCOS,
NK3R antagonism had no detected effect on oestradiol concentra-
tions, which is in contrast to healthy women administered this drug
during the follicular phase of the menstrual cycle, where reduced oes-
tradiol secretion was thought to have increased (or prevented a de-
crease) in FSH release (Skorupskaite et al., 2018a). The absence of a
detected change in oestradiol concentrations may reflect the dysregu-
lated follicular development characteristic of PCOS as well as the lim-
ited changes in LH and FSH, and the short duration of treatment.
Kisspeptin-10 stimulated LH secretion in women with PCOS, al-
though this effect was modest compared to the response to the same
Figure 3 Correlation between oestradiol concentrations and LH response to kisspeptin-10 in with and without NK3Ra.
Kisspeptin-10 response on LH secretion was positively related to oestradiol levels (r2 ¼ 0.59, P< 0.05), whilst this was not seen with NK3Ra treat-
ment (r2 ¼ 0.07, ns).
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..dose in healthy women under high oestrogen exposure (Skorupskaite
et al., 2016). Although obesity can be associated with blunted LH
pulse amplitude, and all the participants in the study but one were
obese, this study does not adequately explore this association.
Likewise, kisspeptin-54 was ineffective in stimulating LH secretion in
normal women in the early follicular and luteal phases, despite eliciting
a marked response in the preovulatory phase (Dhillo et al., 2007;
Chan et al., 2012; Jayasena et al., 2011). A close relationship between
the oestrogenic environment and the response to kisspeptin was
shown here with a direct positive relationship with oestradiol concen-
trations, thus this relationship is present in women with PCOS as well
as in normal women (Narayanaswamy et al., 2016a; Skorupskaite
et al., 2016). However, the relationship between oestradiol concentra-
tions and the LH response to kisspeptin-10 was absent during NK3Ra
treatment, as we have previously reported in normal women
(Skorupskaite et al., 2016). The LH hypersecretion which is character-
istic of PCOS is thought to be driven by oestrogen levels (Rebar et al.,
1976). These data therefore indicate that a key aspect of the NKB
component of KNDy neurone function in both normal women and
those with PCOS is to sense and modulate the effect of the ambient
oestrogenic signal, and thus determine the kisspeptin signal to the
GnRH neurone. This is likely to be of importance in determining the
precise regulation of LH secretion, which is so critical for the regula-
tion of ovarian steroidogenesis and follicle development.
The stimulatory effect of kisspeptin-10 on LH secretion was pre-
served during NK3Ra treatment, despite partially suppressed LH con-
centrations. Intriguingly, these data also showed stimulation of FSH
secretion by kisspeptin-10 during NK3Ra treatment, but not by kiss-
peptin infusion without NK3R antagonism. An FSH response to kiss-
peptin has been minimal and inconsistent in previous studies (Dhillo
et al., 2007; Jayasena et al., 2011; Chan et al., 2012; Skorupskaite
et al., 2014). The background reduced GnRH secretion pattern might
have allowed a stimulatory effect to be detected with the detailed
blood sampling protocol used here. That NKB signalling is functionally
upstream of kisspeptin has been previously demonstrated in patients
with inactivating mutations in the NKB-NK3R pathway as well as in an-
imal studies (Billings et al., 2010; Corander et al., 2010; Navarro et al.,
2011; Ramaswamy et al., 2011; Garcia-Galiano et al., 2012; Young
et al., 2013). This relationship is maintained in PCOS, with high endog-
enous GnRH/LH pulsatile secretion compared to the reduced pulsatile
secretion in patients with NKB/NK3R inactivating mutations.
However, having performed an array of clinical studies in healthy men
and women in different states of LH pulsatile secretion and sex-steroid
environment using a consistent protocol of NK3R antagonism for 7
Figure 4 Analysis of 8-h secretory patterns during vehicle and kisspeptin-10 infusion with and without NK3Ra. (A) Illustrative LH
pulse profile from one subject undergoing vehicle (green diamonds), NK3Ra (purple squares), kisspeptin-10 (red triangles) and NK3Ra followed by
kisspeptin-10 (blue circles) treatment visits. Mean LH pulse frequency (B), secretory mass of LH per pulse (C), basal (non-pulsatile) LH secretion
(D), pulsatile LH secretion (E) and the relative orderliness/regularity of LH secretory pattern (F) during vehicle and kisspeptin-10 infusion with
(n¼ 8) and without (n¼ 7) pre-treatment with NK3Ra. The NK3Ra significantly reduced LH pulse frequency. While Kp-10 alone did not affect LH
pulse frequency, it did increase it in the presence of NK3Ra. Pulsatile LH secretion and LH secretory mass were increased by Kp-10, but not affected
by NK3Ra. Basal LH secretion was reduced by NK3Ra, but was not stimulated by Kp-10 alone or with NK3Ra. Both NK3Ra and Kp-10 increased the
relative orderliness/regularity of LH secretory pattern (i.e. reduced ApEn). Mean § SEM. *P< 0.05.
NKB-kisspeptin axis in PCOS 1427
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..days and exogenous kisspeptin-10 administration (Skorupskaite et al.,
2016, 2017, 2018a,b) (Tables II and III), we demonstrate a more com-
plex interaction between those hypothalamic neuropeptides than a
simply direct interaction. In men, LH secretion was decreased with the
NK3Ra, but this did not affect an immediate stimulatory LH response
to kisspeptin (Skorupskaite et al., 2017). In contrast, the hypothalamo-
pituitary-gonadal (HPG) axis in hypo-oestrogenic postmenopausal
women was refractory to any manipulation by kisspeptin and NK3Ra,
suggesting that the loss of negative oestrogen feedback has an overrid-
ing impact (Skorupskaite et al., 2018b). That NK3Ra abolished the
positive correlation between serum oestradiol and LH response to
kisspeptin in women PCOS suggests an additional level of interaction
between kisspeptin and NKB; similarly, in healthy women, under high
exogenous oestrogen exposure, NK3Ra shortened the LH response
to kisspeptin-10 and disrupted the relationship between the kisspeptin
effect and oestradiol concentrations (Skorupskaite et al., 2016).
Indeed, the orderliness and regularity of LH secretion was here shown
to be increased with administration of either kisspeptin-10 or NK3Ra
in women with PCOS. A potential inhibitory action of NKB itself was
suggested in healthy men, as the stimulatory LH response to co-
infusion of kisspeptin-54 and NKB was significantly lower than with
kisspeptin alone (Narayanaswamy et al., 2016b); however we have
found no evidence of a stimulatory effect of NK3R antagonism in any
of the human models thus far studied.
In addition to the overall fall in LH secretion during treatment with
NK3Ra, we demonstrate a reduction in the frequency of LH pulses as
well as in basal LH secretion, implying that similar changes in the pat-
tern of GnRH release were also achieved. These findings are consis-
tent with low LH pulsatile secretion observed in patients with genetic
defects leading to impaired NKB signalling (Young et al., 2013) and in a
randomized controlled trial in women with PCOS administering the
same NK3Ra (George et al., 2016). Antagonism of NKB signalling
appears to suppress LH pulse frequency uniformly in states associated
with increased LH pulsatility, such as in women during the late follicu-
lar phase (Skorupskaite et al., 2016) and in postmenopause
(Skorupskaite et al., 2018b) and in gonadectomized animals (Fraser
et al., 2015; Li et al., 2015), whereas no effect is seen in states of
slower LH pulse frequency, such as in women during the early follicu-
lar phase (Skorupskaite et al., 2018a) and in men (Skorupskaite et al.,
2017) (Table III). This suggests that these states of higher LH pulse fre-
quency may be driven by NKB signalling, with this pathway having less
importance at lower frequencies. NK3Ra also improved the orderli-
ness and regularity of LH pulses in women with PCOS, which was also
seen with kisspeptin-10 for the first time. Dysregulation and hyperse-
cretion of LH associated with PCOS may derive from disordered hy-
pothalamic kisspeptin and/or NKB secretion and their downstream
effects on the pattern of GnRH release, suggesting new paradigms in
the neuropathophysiology of PCOS.
Kisspeptin-10 increased the mass of LH released per pulse and the
overall mass of LH secreted in a pulsatile pattern in women with
PCOS, consistent with increased LH concentrations. Overall, the
effects of kisspeptin-10 on pulsatile GnRH/LH secretion in women
with PCOS were similar to those seen in healthy women during exog-
enous oestradiol-induced LH surge, apart from the increased LH pulse
frequency in the latter (Skorupskaite et al., 2016) (Table III). However,
kisspeptin-10 increased LH pulse frequency after the pulses were
slowed down by pre-treatment with the NK3Ra. Similarly, to the
above considerations regarding a higher LH pulse frequency being
needed for NKB antagonism to suppress LH pulsatility, there may be a
threshold of LH pulse frequency beyond which further stimulatory
effects of kisspeptin cannot be achieved, in the presence of steroidal
feedback. Similarly, infusion of kisspeptin-10 restored low LH pulse fre-
quency in men and women with inactivating mutations in NKB signal-
ling (Young et al., 2013). Although this is consistent with the overall
hierarchy whereby NKB is functionally upstream of kisspeptin, co-
administration of NK3Ra prevented kisspeptin-induced changes in the
pattern of LH and inferred GnRH release (Table III), further indicating
the complex interactions between those hypothalamic neuropeptides.
Reduced LH secretion through NK3R antagonism seen in this study
may be of therapeutic application in women with PCOS. In a short-
duration randomized controlled trial of this approach, serum testoster-
one levels were reduced (George et al., 2016) but trials of sufficient
duration to see clinical benefit have not yet been reported. The reduc-
tion in LH hypersecretion with NK3R antagonism may be of value for
the induction of ovulation in women with PCOS, although the small
reduction in FSH reported here may also impact on that. The pheno-
typic diversity of women with this condition, particularly in relation to
lean/obese status, is also very relevant and was not explored in this
............................................................................................................................................................................................................................
Table II Summary table showing effects of KP-10 andNK3Ra (MLE4901) administration, by a consistent protocol, on gonad-
otropin secretion in different states of LHpulsatility and sex-steroid environments inmen andwomen.
Men Postmenopausal women Premenopausal women Women with PCOS
Study Skorupskaite et al. (2017) Skorupskaite et al. (2018b) Skorupskaite et al. (2016) Present data
LH status Normal Very high LH surge model High
Sex-steroid feedback Negative Loss of negative Negative then positive Dysregulated
NK3Ra response Decreased LH Marginal LH decrease Marginal decrease in basal LH Decreased LH
Decreased FSH No FSH effect Increased FSH Decreased FSH
KP-10 response Increased LH No LH/FSH effect Increased LH and FSH Increased LH
No FSH effect
KP-10 and NK3Ra (vs KP-10 alone) No change No LH/FSH effect Shorter KP response Increased LH and FSH
Loss of relationship with
oestradiol
Loss of relationship with
oestradiol
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study, due to the small number of women included. Kisspeptin admin-
istration has been explored in women with PCOS to induce ovulation
(Romero-Ruiz et al., 2019) and to reduce the risk of ovarian hypersti-
mulation syndrome in assisted reproduction (Abbara et al., 2015).
The work described above forms part of series of reproductive neu-
roendocrine studies in humans (Skorupskaite et al., 2016, 2017,
2018a,b). The small number of subjects is an important limitation, al-
though they have been studied using consistent protocols and random-
isation. The complexity of the study has precluded the involvement of
large patient numbers to adequately explore the possibility that some
phenotypes of PCOS may show different responses. Five women with
PCOS out of the ten recruited participated in all four arms of the stud-
ies which may further limit the generalisability of the data. Although a
specific PCOS phenotype was not selected for this study, our data
show a degree of consistency of response that does not indicate rele-
vance to only certain subgroups.
The KNDy system is a key mediator of the effects of sex steroids
and other, e.g. metabolic, factors on GnRH secretion and thus the re-
productive system. The present data suggest a specific role for NKB in
mediating the influence of circulating oestrogen levels, but in the con-
text of PCOS, it will be important to investigate the influence of
obesity on kisspeptin and NKB modulation of GnRH secretion Anti-
Mullerian hormone (AMH) has also been implicated as a regulator of
GnRH secretion (Cimino et al., 2016), and there may be effects of
long-term increased hypothalamic exposure to AMH and oestradiol
on the kisspeptin/NKB system and its interaction with other hypotha-
lamic neurotransmitter pathways (Moore and Campbell, 2016).
In summary, kisspeptin-10 infusion in women with PCOS increased
LH secretion, with a direct relationship to oestradiol exposure. NK3R
antagonism reduced LH secretion and pulsatility, and whilst the LH re-
sponse to kisspeptin-10 was preserved, its relationship with circulating
oestradiol concentrations was not. Although kisspeptin-10 increased
the frequency of LH pulses, changes in other parameters of LH secre-
tory pattern were prevented when co-administered with the NK3Ra.
These data thus indicate that NKB and kisspeptin regulate GnRH se-
cretion in women with PCOS and that there is a complex rather than
purely direct interaction between those neuropeptides in determining
the precise pattern and degree of GnRH/LH secretion. Whilst these
data show largely similar effects to those seen in normal women, the
differences in both the effects of NK3R antagonism and response to
kisspeptin-10 may be attributable to the precise level of sex-steroid
feedback, and do not indicate major differences in the neuroendocrine
regulation of LH secretion in PCOS at the level of the KNDy neurone.
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Table III Effects on NK3R antagonism, kisspeptin-10 infusion and their combination on various parameters of pulsatile na-
ture of LH, and by inferenceGnRH secretion, in healthymen andwomen at different stages of reproductive life.
Group Men Postmenopausal
women—with
hot flushes
Premenopausal
women—early
follicular phase
Premenopausal women—LH
surge model
Women with PCOS
Study Skorupskaite
et al. (2017)
Skorupskaite
et al. (2018b)
Skorupskaite
et al. (2018a)
Skorupskaite et al. (2016) Present data
Treatment/Pulsatility
parameter
NK3Ra NK3Ra NK3Ra NK3Ra KP-10 NK3Ra and
KP-10
NK3Ra KP-10 NK3Ra and
KP-10
LH pulse frequency No change Decrease No change Decrease Increase Increase Decrease No change Increase
LH mass per pulse No change Increase No change No change Increase Increase No change Increase No change
Basal LH Decrease Decrease Decrease No change Decrease No change Decrease No change No change
Pulsatile LH Decrease No change No change No change Increase Increase No change Increase No change
ApEn (irregularity) Decrease No change No change Decrease Decrease Decrease Decrease Decrease No change
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